Table 2 Summary of the eligible studies on PLR in predicting survival, treatment response, and diagnosis in patients with ovarian cancer

Asher et al. [72], 2011; Zhang et al. [75], 2015; Wang et al. [49], 2016; Miao et al. [50], 2016; Hu et al. [73], 2016; Farolfi et al. [39], 2018; Ceran et al. [40], 2019; Jammal et al. 2020[81]; Chon et al. [74], 2021; Ramón-Rodríguez et al. [82], 2022

OCP: underwent surgery, with CRS followed by platinum-based CT

EOCP: receiving platinum-based CT, in FIGO stage III-IV EOCP treated with first-line CT or in CTB, underwent surgery, with advanced stage;

HGSOCP: underwent surgical resection of primary cancers;

Ovarian peritoneal carcinomatosis: underwent CRS with HIPEC

Predicting survival: OS, PFS, and DFS

Ashrafganjoe et al. [56], 2016; Sastra et al. [57], 2022; Raungkaewmanee et al. [78], 2012; Winarno et al. [59], 2021

168 EOCP underwent primary staging exploratory laparotomy; 54 Indonesian EOCP underwent primary exploratory laparotomy; 166 EOCP underwent surgery; 95 EOCP underwent platinum CT after cytoreduction surgery

Predicting treatment response: surgical outcome, efficacy of CT

Yildirim et al. [62], 2014; Yildirim et al. [63], 2015; Ozaksit et al. [79], 2015; Polat et al. [30], 2016; Eo et al. [65], 2018; Wang et al. [80], 2021;Li et al. [66], 2021; Yun et al. [67], 2022

316 OCP with documented benign and 253 OCP with malignant adnexal masses underwent primary surgery; 306 patients with adnexal masses underwent surgical resection; 196 adolescent females with adnexal masses; 275 women with sonographically detected ovarian tumor; 229 EOCP; 43 OCP with recurrence; 207 patients with benign ovarian masses and 887 EOCP who underwent surgical resection; 630 patients with ovarian tumors

Predicting diagnosis: malignant or not, malignant degree, advanced-stage, recurrence, histotypes, benign or borderline tumors